A Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEP of the European Pharmacopoeia monograph is often referred to as a Nolvadex, Istubal, Valodex, Tamoxifen Citrate Certificate of Suitability (COS). The purpose of a Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nolvadex, Istubal, Valodex, Tamoxifen Citrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nolvadex, Istubal, Valodex, Tamoxifen Citrate to their clients by showing that a Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEP has been issued for it. The manufacturer submits a Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEP holder for the record. Additionally, the data presented in the Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nolvadex, Istubal, Valodex, Tamoxifen Citrate DMF.
A Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nolvadex, Istubal, Valodex, Tamoxifen Citrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nolvadex, Istubal, Valodex, Tamoxifen Citrate suppliers with CEP (COS) on PharmaCompass.